The predictive strength of next-generation sequencing MRD detection for relapse compared with current methods in childhood ALL

Blood

Volumn 126, Issue 8, 2015, Pages 1045-1047

  Kotrova, Michaela ^a   Muzikova, Katerina ^a   Mejstrikova, Ester ^a   Novakova, Michaela ^a   Bakardjieva Mihaylova, Violeta ^a   Fiser, Karel ^a   Stuchly, Jan ^a   Giraud, Mathieu ^b   Salson, Mikaël ^b   Pott, Christiane ^c   Brüggemann, Monika ^c   Füllgrabe, Marc ^c   Stary, Jan ^a   Trka, Jan ^a   Fronkova, Eva ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b UNIV LILLE   (France)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE LYMPHOBLASTIC LEUKEMIA; CHILDHOOD LEUKEMIA; HUMAN; LETTER; LEUKEMIA RELAPSE; MINIMAL RESIDUAL DISEASE; NEXT GENERATION SEQUENCING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; HIGH THROUGHPUT SEQUENCING; NEOPLASM, RESIDUAL; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PREDICTIVE VALUE; PROCEDURES; RECURRENT DISEASE;

HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; NEOPLASM, RESIDUAL; POLYMERASE CHAIN REACTION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PREDICTIVE VALUE OF TESTS; RECURRENCE;

EID: 84940094339     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-07-655159     Document Type: Letter

References (10)

1. Van Dongen JJM, van der Velden VHJ, Brüggemann M, Orfao A. Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies. Blood. 2015;125(26):3996-4009.
2. Logan AC, Zhang B, Narasimhan B, et al. Minimal residual disease quantification using consensus primers and high-throughput IGH sequencing predicts post-transplant relapse in chronic lymphocytic leukemia. Leukemia. 2013;27(8):1659-1665.
3. Faham M, Zheng J, Moorhead M, et al. Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia. Blood. 2012;120(26):5173-5180.
4. Ladetto M, Brüggemann M, Monitillo L, et al. Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders. Leukemia. 2014;28(6):1299-1307.
5. Wu D, Emerson RO, Sherwood A, et al. Detection of minimal residual disease in B lymphoblastic leukemia by high-throughput sequencing of IGH. Clin Cancer Res. 2014;20(17):4540-4548.
6. van Dongen JJ, Langerak AW, Brüggemann M, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia. 2003;17(12):2257-2317.
7. Fronkova E, Mejstrikova E, Avigad S, et al. Minimal residual disease (MRD) analysis in the non-MRD-based ALL IC-BFM 2002 protocol for childhood ALL: is it possible to avoid MRD testing? Leukemia. 2008;22(5):989-997.
8. Volejnikova J, Mejstrikova E, Valova T, et al. Minimal residual disease in peripheral blood at day 15 identifies a subgroup of childhood B-cell precursor acute lymphoblastic leukemia with superior prognosis. Haematologica. 2011;96(12):1815-1821.
9. Basso G, Veltroni M, Valsecchi MG, et al. Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow. J Clin Oncol. 2009;27(31):5168-5174.
10. Giraud M, Salson M, Duez M, et al. Fast multiclonal clusterization of V(D)J recombinations from high-throughput sequencing. BMC Genomics. 2014;15:409.